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Background: The safety and efficacy of racecadotril to treat acute watery diarrhea (AWD) in 
children is well established, however its cost effectiveness for infants and children in Europe 
has not yet been determined.
Objective: To evaluate the cost utility of racecadotril adjuvant with oral rehydration 
  solution (ORS) compared to ORS alone for the treatment of AWD in children younger than 
5 years old. The analysis is performed from a United Kingdom National Health Service (NHS) 
perspective.
Methods: A decision tree model has been developed in Microsoft® Excel. The model is 
  populated with the best available evidence. Deterministic and probabilistic sensitivity analyses 
(PSA) have been performed. Health effects are measured as quality-adjusted life years (QALYs) 
and the model output is cost (2011 GBP) per QALY. The uncertainty in the primary outcome is 
explored by probabilistic analysis using 1000 iterations of a Monte Carlo simulation.
Results: Deterministic analysis results in a total incremental cost of -£379 in favor of 
racecadotril and a total incremental QALY gain in favor of racecadotril of +0.0008. The 
observed cost savings with racecadotril arise from the reduction in primary care reconsultation 
and secondary referral. The difference in QALYs is largely attributable to the timely 
  resolution of symptoms in the racecadotril arm. Racecadotril remains dominant when base 
case   parameters are varied. Monte Carlo simulation and PSA confirm that   racecadotril 
is the dominant treatment strategy and is almost certainly cost effective, under the central 
assumptions of the model, at a commonly used willingness to pay proxy threshold range of 
£20,000–£30,000 per QALY.
Conclusion: Racecadotril as adjuvant therapy is more effective and less costly compared to 
ORS alone, from a UK payer perspective, for the treatment of children with acute diarrhea.
Keywords: cost effectiveness, health economic model, infant, QALY, racecadotril, acute 
watery diarrhea
Introduction
Despite advances in medicine over the last decades, acute watery diarrhea (AWD) 
remains the cause of substantial morbidity in developed countries.1 In England, 
approximately 150,000 children younger than 5 years old present with symptoms of 
vomiting and diarrhea (gastroenteritis) each year. In 2007–2008, approximately 37,000 
children were admitted to secondary care hospitals.2 Oral rehydration solution (ORS) 
is the standard of care to replace fluid loss, but it has no impact on the duration or 
severity of diarrhea. There is limited availability of alternate therapies, especially those 
indicated for infants and children, which reduce the duration and severity of diarrhea. 
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  Racecadotril is a nonopiate enkephalinase inhibitor with a 
unique mechanism of action with rapid onset.3 The basally 
abundant enzyme enkephalinase degrades endogenous 
enkephalins in the intestinal mucosa that otherwise exhibit 
proabsorptive and antisecretory properties. Racecadotril 
prevents the degradation of enkephalins and thereby promotes 
antisecretion.4 Furthermore, it has no effect on intestinal 
motility and therefore no enteropooling or rebound constipa-
tion is experienced. There is also no respiratory depression or 
other central neurotoxicity effect,5–7 making this a favorable 
drug option, especially for children.4
Pediatric presentations of racecadotril were first 
authorized in France in 1999 and today it is approved and 
widely used in seven European countries (France, Spain, 
Italy, Portugal, Greece, Bulgaria, and Romania) and 
outside Europe. The efficacy of racecadotril has been well 
established in clinical studies and in an individual patient data 
meta-analysis.8–19 In addition, the safety of racecadotril in 
children has been demonstrated in clinical studies, including a 
large pre- and postaccess study showing that racecadotril has 
a favorable adverse event (AE) profile in children.9,12–14,19–21 
Despite its proven safety and efficacy, the cost effectiveness 
of racecadotril for infants and children has not yet been 
determined in Europe. The objective of this analysis is to 
evaluate the cost effectiveness of racecadotril from a UK 
payer perspective.
Evidence base
A systematic literature search and review identified   potential 
clinical studies and quality of life (QoL) and resource 
utilization data to populate the model. Focused literature 
searches have been performed in databases, including 
PubMed, Embase, and the Cochrane library. A detailed 
search strategy is available upon request. Available and 
relevant evidence has been weighed against each other to 
determine the highest quality for inclusion in the model.
Model
Structure
The Racecadotril in Acute Watery Diarrhea (RAWD) model 
is a decision tree programmed in Microsoft® Excel (Micro-
soft, Redmond, WA) and developed to evaluate the treatment 
of racecadotril as adjuvant to ORS (hereafter referred to only 
as racecadotril). The chosen comparator is ORS, which is 
the currently recommended treatment in the National Health 
Service (NHS) according to the National Institute for Health 
and Clinical Excellence (NICE).2 The model performs deter-
ministic and probabilistic sensitivity analyses and considers 
costs and outcomes from the United Kingdom (UK) NHS 
perspective. Health effects are   measured as quality-adjusted 
life years (QALYs) and the model output is cost (GBP) per 
QALY. The model uses a time horizon of 6 days based on 
the general assumption that nonsevere acute diarrhea is self-
limiting to 6 days, and therefore no discounting is applied. 
According to the decision tree, children with symptoms of 
AWD present to primary care and are prescribed racecadotril 
or ORS alone. Forty-eight hours after the start of treatment, 
children with unresolved symptoms will reconsult at primary 
care, whereupon they may continue treatment as before, or if 
symptoms have worsened, they may be referred to secondary 
care. The face validity of this treatment pathway has been 
verified by two clinical experts22,23 and appears to agree 
with the literature reviewed and the management of diarrhea 
alluded to in the guidelines of the World Gastroenterology 
Organization, NICE, and the World Health Organization.1,2,24 
The models’ structure is illustrated in Figure 1.
Base case parameters
Clinical effectiveness data is available from ten indi-
vidual studies,8–15 two systematic reviews,16,17 and two 
meta-analyses.18,19 The first systematic review, published in 
2007,16 includes three studies in the analysis.8,9,11 The results 
show that 48-hour stool output is significantly less in the 
racecadotril group than in the control group, with a standard-
ized mean difference (SMD) of -0.67; 95% confidence interval 
[CI] (-0.9 to -0.44). The final outcome assessed is cure in 
5 days or less, and pooled results show no significant difference 
between the racecadotril group and the control group (risk ratio 
[RR] 1.1; 95% CI: 0.97 to 1.21). It can, however, be argued 
that this endpoint is flawed because all patients recovered by 
day five; the difference in recovery is significant around day 
two, as demonstrated by Lehert et al.19
The second systematic review, performed in 2008,17 
includes two studies in the analysis.8,9 It shows that stool 
volume at 48 hours is less in the racecadotril group than in 
the control group (SMD -0.65; 95% CI: -0.88 to -0.42). 
Again, there is no difference in the proportion of children who 
recover by day five (RR 0.73; 95% CI: 0.29 to 1.81).17 Again, 
individual patient meta-analysis shows that the difference in 
recovery is significant around day two.19
The first meta-analysis18 includes four studies8,9,11,12 and 
shows a significant difference in stool output at 48 hours in 
favor of racecadotril (P = 0.00001).8,9 Heterogeneity between 
studies was not found statistically significant (P = 0.86; 
I2 = 0%). The study also shows a statistically significant dif-
ference for children who revisited a pediatrician or emergency 
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department 48 hours after treatment favoring racecadotril 
(RR 0.62; 95% CI: 0.40 to 0.97; P = 0.04) with homogeneity 
between studies (P = 0.41; I2 = 0%).11,12 The study further 
confirmed that racecadotril is comparable to ORS alone with 
respect to safety and tolerability.20
The second meta-analysis by Lehert et al includes nine 
studies (one publication reports two trials)8–15 and aims to 
overcome the shortcomings of previous studies in general, 
which do not include all existing trials, estimate treatment 
effect using meta-analysis in literature, pool different end-
points, and do not explore the influence of baseline conditions 
on treatment effect (eg, dehydration level, rotavirus status, 
age, inpatient/outpatient setting, country).19 The study is an 
individual patient (raw data) meta-analysis that includes 
eight out of the ten available studies19 (one excluded study 
compares racecadotril to loperamide21 and the second was an 
open-label study that did not meet quality requirements).25 
It is considered by the model developers to be the highest 
quality evidence and considers all relevant studies, including 
those with less favorable results for racecadotril, it is therefore 
used for the RAWD model. Results show that twice as many 
patients recover at any time with the racecadotril regimen: 
hazard ratio (HR) 2.04 (95% CI: 1.85 to 2.32; P , 0.001).19 
To convert this to a proportion in the model, a Weibull 
distribution is fitted to the data and the proportional hazards 
assumption is used to vary the efficacy of the racecadotril 
arm with respect to the ORS arm. Using this distribution, 
the median for the racecadotril and ORS arms is reached at 
1.75 and 2.79 days, respectively, and results in the reported 
HR at 2.75 days in agreement with the study data, which 
suggests a suitable fit. This distribution shows that after 
48 hours of treatment, 58% and 26% of patients respond in the 
racecadotril and ORS arms, respectively. These results appear 
to correspond to the reductions in 48-hour stool volume 
and 48-hour stool output reported in other studies.16–19 As a 
conservative estimate, in the model it has been assumed that 
all children with unresolved symptoms at 48 hours reconsult 
their primary care facility.
A study by Cojocaru et al evaluated children presenting 
to an emergency department (A & E) for diarrhea.11 Children 
were admitted for 24 hours at presentation and a scheduled 
visit on day 2 was included in the study protocol for all 
patients. Additional medical visits (.day 2 #day 7) were 
required for 34% of children in the ORS arm and 18% of 
children in the racecadotril arm (P , 0.05).11 Secondary 
referral was measured after day 2. The details of this study 
do not typically represent the scenario modeled, which is the 
UK primary care setting; specifically, the model does not 
consider children presenting to A & E instead of primary care 
for AWD. Only one study includes secondary referral data 
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Figure 1 Decision tree model structure.
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at 48 hours and demonstrates fewer hospital admissions for 
racecadotril compared to ORS at 24 hours (P , 0.005) and 
48 hours (P , 0.0001); it has been included in the model.13
It is difficult to measure QoL in young children, however, 
there are three potentially relevant publications. In one, 
Huppertz et al analyzes parental perception of the impact 
of diarrhea on the QoL of their children.26 A second study 
evaluates the QoL in children with gastroenteritis in Canada.27 
A third study rates the QoL of children with acute infectious 
gastroenteritis.28 In this study, two health state descriptions 
(for primary and secondary care) have been rated by general 
practitioners and pediatricians across five geographic areas 
in the UK. EuroQoL (EQ-5D) scores have been converted to 
utility values using UK population data and the time trade-off 
method.28 Secondary care ratings from general practitioners 
are more conservative than pediatricians and are therefore 
used in the model to calculate an average for children younger 
than 5 years old. It has been assumed that children with 
AWD have comparable QoL to those with acute infectious 
diarrhea; the same utility values have been used elsewhere 
for rotavirus infection.29 The Martin, Cottrell, and Standaert 
study is considered the highest quality and most relevant 
evidence because it includes EQ-5D data; it is based on UK 
population norms and utilizes the time trade-off approach 
and has therefore been used in the RAWD model.28
For the AE data, the following frequencies for racecadotril 
vs ORS are reported: 12.4% vs 16.2%,20 11.6% vs 10.1%,19 
19.1% vs 20.2%,12 11.5% vs 22% (vs loperamide),21 10% 
vs 7% (vs placebo),9 5%–6% (ORS arm not reported),14 and 
6% (ORS arm not reported).13 The highest frequency of AEs 
comes from a study by Santos et al, involving 84 patients.12 
By far the most extensive data comes from a pre-and postac-
cess analysis of individual case safety reports and clinical 
trial AEs from a total sample of 1129 records.20 The Baumer 
and Joulin study is based on the largest sample size and is 
comparable and/or conservative in comparison to the other 
estimates listed above; it is considered fair to include it as 
the highest quality evidence for the frequency of AEs in the 
model.
The drug cost is calculated at a dose of 1.5 mg per 
kilogram (kg) of body weight administered three times daily. 
The average weight of a child is assumed to be 13.5 kg, based 
on an average estimate from multiple sources.30–33 ORS has 
been conservatively estimated to be administered after every 
stool in accordance with the definition of AWD, which states 
at least three watery stools are passed in 24 hours.1 The 
weighted average cost of an ORS sachet is calculated at £0.29 
per sachet, at a total daily cost of £0.88.34 The drug cost of 
racecadotril is £0.42 per 10 mg sachet35, resulting in a total 
daily drug cost of £3.82 (including ORS).
The national average cost of a primary care consultation 
of £36 (based on an 11.7 minute consultation) and the 
national average cost of secondary care for a nonelective 
short inpatient stay of £523 are used in the model.36 
Hospital Episode Statistics for England (Inpatient) 
2010–2011 are used to estimate the average length of stay 
for deterministic analysis.37 Hospital Resource Group 4 
(HRG4) and ICD-1038 data are shown in Table 3. The value 
of 2.65 days (3 days) is used for deterministic analysis 
based on the average of ICD-10 A00-A09 (intestinal 
infectious diseases) and HRG4 PA21B (infectious and 
noninfectious gastroenteritis without complications and 
comorbidities) codes, those being the only codes with 
actual numbers of children recorded in the relevant age 
group (number of children aged 0–14 years: 37,889 for 
PA21B; 29,689 for A00-A09).37,38
For AEs, Baumer and Joulin report the most common 
AE to be vomiting (5.1% vs 5.8%), fever (2.3% vs 4.6%), 
and allergic AEs (1.3% vs 4.1%) for racecadotril and ORS, 
respectively.20 Half of all AEs reported by individual case 
safety reports are classified as “skin and subcutaneous 
tissue disorders”, which are mainly rash and urticaria.20 In 
the absence of available AE cost data, an average weighted 
cost for vomiting (£15), allergic AEs (£20), and fever (£50) 
is used in the model. A summary of the model parameters 
is shown in Table 1.
Model assumptions
The RAWD model assumes that children presenting with 
clinical dehydration at the first primary care consultation are 
referred immediately to secondary care in accordance with 
current clinical practice guidelines and are not included in 
the modeled population.2 The treatment effect in the model 
is irrespective of diarrhea duration prior to the first primary 
care consultation and etiology of diarrhea. Also in accordance 
with practice guidelines and confirmed by experts in primary 
care, stool sampling is not routine practice and is not included 
in the model.22,23 It is assumed that when symptoms of AWD 
resolve, the treatment stops and the daily drug cost is no 
longer incurred. Furthermore, if diarrhea has not resolved 
at first and second primary care consultations, and if there 
is no secondary referral, the diarrhea will be self-limiting 
and resolve at day 6 (maximum treatment duration, 6 days). 
The model considers the drug cost of actual sachets used for 
each regimen and does not include the effects of wastage or 
compliance.
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Results
The deterministic analysis calculates the cost and benefits over 
a six-day time horizon. The total drug cost for racecadotril 
vs ORS is £12.17 vs £3.03, primary care costs are £51.12 
vs £62.64, secondary care costs are £40.20 vs £416.82, and 
AEs cost £0.35 vs £0.46 per patient. The total average cost 
for racecadotril and ORS treatment regimens is £103.84 vs 
£482.95, respectively. The most notable cost savings with 
racecadotril arises from the reduction in secondary care 
costs. The cost comparison data is summarized in Table 2. 
The total incremental cost is -£379 in favor of racecadotril. 
The total incremental QALY gain in favor of racecadotril 
is +0.0008 for a 6-day period. The difference in QALYs is 
largely attributable to the timely resolution of symptoms in 
the racecadotril arm. The incremental cost effectiveness ratio 
is -£473,750 with racecadotril being the dominant treatment 
strategy, which means that racecadotril (adjuvant) is more 
efficacious and less costly than ORS alone under the central 
assumptions of the model.
Uncertainty
For the deterministic analysis, when the “average length of 
stay for secondary care” is reduced from three to one night, 
the incremental cost is -£128 and the incremental QALY 
gain is +0.0016, resulting in a dominant incremental cost 
effectiveness ratio of -£80,000 in favor of racecadotril. 
For AEs, when the least favorable estimate12 is entered for 
both regimens, the resultant incremental cost effective-
ness ratio is -£494,830.12 When both parameters (LOS 
and AE) are varied simultaneously, the result is –£81,885, 
with racecadotril remaining the dominant treatment 
strategy. Varying deterministic base case estimates by 20% 
(constrained by maximum and minimum values) shows that 
the model is most sensitive to the QoL estimate of a “well” 
person. The value is taken from a UK national survey com-
missioned by the Department of Health and published as a 
working paper by the Centre for Health Economics, York 
University.39 A total of 3395 adults in the UK were inter-
viewed using the EQ-5D.39 The base case value of 0.94 was 
used, which is the mean for those aged under 25 years and 
is the closest approximation to a child’s full health that is 
available, to the best of the model developers’ knowledge.
To evaluate the uncertainty in the parameter estimates, 
a probabilistic sensitivity analysis has been performed by 
fitting distributions (shown in Table 1) to the deterministic 
estimates and running 1000 iterations of a Monte Carlo 
simulation. Probabilistic sensitivity analysis shows that 
racecadotril is the dominant treatment strategy, it being 
less costly and more effective compared to ORS alone, as 
shown in Figure 2. The cost effectiveness acceptability curve 
shows that the racecadotril strategy is almost certainly cost 
effective at a proxy willingness-to-pay threshold range of 
£20,000–£30,000 per QALY.
Discussion
This model has been developed from a UK perspective and 
all cost and utility data are derived from British sources. 
The reader should consider that the available studies for the 
other base case parameters originate from Europe (three from 
France8,11,21 [one study vs loperamide] and two from Spain12,13) 
Table 1 Base case parameters
Base case parameter Deterministic value Probabilistic distribution Source
Primary care
Proportion resolving at 48 hours* ORS 26% Weibull Lehert et al19
Proportion resolving at 48 hours R + ORS 58% Weibull Lehert et al19
Secondary care
Secondary referral at 48 hours ORS 36% Beta Alvarez Calatayud et al13
Secondary referral at 48 hours R + ORS 6% Beta Alvarez Calatayud et al13
AEs
Frequency of AE ORS 16% Beta Baumer and Joulin20
Frequency of AE R + ORS 12% Beta Baumer and Joulin20
Quality of life
Average QoL PC , 5 years 0.7345 Beta Martin et al28
Average QoL SC , 5 years 0.6145 Beta Martin et al28
Note: *48 hours from start of treatment.
Abbreviations: ORS, oral rehydration solution; R, racecadotril; AE, adverse events; QoL, quality of life; PC, primary care; SC, secondary care.
Table 2 Cost comparison results (deterministic)
Cost results ORS Racecadotril + ORS
Drug cost £3.03 £12.17
Primary care £62.64 £51.12
Secondary care £416.82 £40.20
Adverse events £0.46 £0.35
Total mean cost per patient £482.95 £103.84
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and the rest of the world (Mexico,14 Guatemala,15 India,10 
and Peru9). It is generally accepted that the five European 
studies are more closely representative of the UK health care 
system. Differences for the rest of the world studies are most 
likely to arise from differences in resource utilization, assum-
ing that children in developing countries are more likely to 
have underlying conditions that predispose them to more 
severe diarrhea and more potential for clinical dehydration 
(eg, malnutrition, etc) and referral. No resource utilization 
(reconsultation and referral) data from the rest of world stud-
ies is used in the model.
The population modeled in this analysis is infants and 
children younger than 5 years old. Regarding clinical effi-
cacy, the Lehert et al meta-analysis included nine studies for 
the determination of diarrhea duration (one study had two 
sets of results).19 The maximum age in all studies is 5 years 
(60 months), except in the Melendez Garcia study, which 
is 71 months.15 The authors note that results are similar 
for infants aged under 1 year old (n = 714; HR 2.01; 95% 
CI: 1.71–2.36; P , 0.001) and toddlers aged over 1 year 
old (n = 670; HR 2.16; 95% CI: 1.83–2.57; P , 0.001). 
The heterogeneity among studies is small (I2 = 0.28).19 The 
QoL data from the Martin, Cottrell, and Standaert study 
includes separate scores for children under 18 months old 
and 18 month to 5 year olds.28 Raw scores have been modi-
fied to account for inability to rate mobility and self-care in 
very young children. An average utility for both age groups 
has been calculated and used in the model.28 For AEs, the 
Baumer and Joulin study does not specify the age range for 
the data included; however, the authors note that the nature 
and frequency of AEs does not differ significantly between 
children aged under 30 months and older children.20 It 
therefore seems reasonable to assess the impact of AWD in 
children younger than 5 years old as a group.
In 2009, NICE issued guidance for vomiting and diarrhea in 
children younger than 5 years old.2 The supplementary costing 
Table 3 HRG4 and ICD-10 data for length of stay
Code Description Age  
0–14 years*
Mean   
LOS
HRG4
FZ36C Intestinal infectious disorders  
without cc
0 4.5
FZ36E Intestinal infectious disorders 
with length of stay 1 day  
or more without major cc
0 4.4
FZ36F Intestinal infectious disorders  
with length of stay 0 days
0 0.4
PA21B Infectious and noninfectious  
gastroenteritis without cc
37 889 0.7
WA06Y Other viral illness without cc 0 1.5
ICD-10 (primary diagnosis summary)
A00-A09† Intestinal infectious diseases 29 689 4.6
Notes: *Number of finished consultant episodes (FCE) relating to patients who 
were up to 14 years of age (inclusive) when the episode began; †includes infantile 
inflammatory diarrhea – bacterial cause (A04), viral cause (A06), and infectious 
gastroenteritis and colitis, unspecified (A09).37,38
Abbreviations: cc, complications and comorbidities; LOS, length of stay.
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Figure 2 Probabilistic sensitivity analysis results.
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statement predicts that implementation of the clinical 
practice guideline is not likely to have significant savings at 
the national level.40 In view of the evidence available at that 
time, this is a reasonable assessment; however, in the light of 
new evidence, there seems to be opportunity for substantial 
cost savings. The model shows that the first cost driver for 
diarrhea in the under-5 age group is the reconsultation rate 
for primary care (not including dehydration). For the UK, 
this is confirmed by experts, who report reconsultation 
rates as high as 30%,23 with recent results from Cegedim 
indicating a 14.3% reconsultation rate in children 4 years 
old and younger.41 As described, studies generally measure 
efficacy using stool output/48 hours, number of diarrheic 
stools, stool volume, and diarrhea duration. The most 
clinically and economically meaningful result seems to 
be diarrhea duration, as this has a direct influence on the 
reconsultation rate for children with unresolved symptoms 
and affects the QoL of children and their caregivers. By 
resolving the symptoms of diarrhea within 48 hours, the 
reconsultation rate can potentially be reduced, with resultant 
cost savings. The second cost driver identified is the 
secondary care admission rate, which not only contributes 
to cost but adds the risk of nosocomial infection.42 Again, 
by timely resolution of diarrhea and avoidance of secondary 
referral costs, the burden of resource utilization is alleviated. 
Furthermore, the model assumes a constant secondary 
referral rate over time; however, it may be that as the 
duration of diarrhea increases, the rate of secondary referral 
increases accordingly. This hypothesis is not extensively 
explored in the current literature and may be a useful 
question for future research. If a differential secondary 
referral rate is proven, then the full benefit of racecadotril 
shortening disease duration in comparison to ORS alone19 is 
underestimated in the RAWD model. A further contributor to 
cost, which also has not been included in the model, arises 
from the impact of diarrhea in children on their parents and 
caregivers. Van der Wielen et al sampled 1102 parents of 
children younger than 5 years old seeking medical care as 
a result of acute gastroenteritis. The proportion requiring 
at least one person to be absent from work was 20%–64% 
for primary care setting and 39%–91% for secondary care 
setting.43 From a broader societal perspective, the cost of 
children’s AWD is therefore likely to be much higher than 
from a payer’s perspective.
Conclusion
The RAWD model demonstrates that, considering the best 
available evidence, racecadotril is cost effective in the 
treatment of AWD in children. The model highlights the 
potential cost savings arising from reduction in diarrhea 
duration and avoidance of reconsultation and referral rates 
in children with diarrhea.
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